NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade

T. Kurashige, Y. Noguchi, T. Saika, Toshiro Ono, Y. Nagata, A. Jungbluth, G. Ritter, Y. T. Chen, E. Stockert, T. Tsushima, H. Kumon, L. J. Old, E. Nakayama

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY. ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.

Original languageEnglish
Pages (from-to)4671-4674
Number of pages4
JournalCancer Research
Volume61
Issue number12
Publication statusPublished - Jun 15 2001

Fingerprint

Transitional Cell Carcinoma
Messenger RNA
Neoplasms
Neoplasm Antibodies
Antibodies
Carcinoma in Situ
Reverse Transcription
Immunohistochemistry
Monoclonal Antibodies
Staining and Labeling
Polymerase Chain Reaction
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kurashige, T., Noguchi, Y., Saika, T., Ono, T., Nagata, Y., Jungbluth, A., ... Nakayama, E. (2001). NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Research, 61(12), 4671-4674.

NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma : Correlation with tumor grade. / Kurashige, T.; Noguchi, Y.; Saika, T.; Ono, Toshiro; Nagata, Y.; Jungbluth, A.; Ritter, G.; Chen, Y. T.; Stockert, E.; Tsushima, T.; Kumon, H.; Old, L. J.; Nakayama, E.

In: Cancer Research, Vol. 61, No. 12, 15.06.2001, p. 4671-4674.

Research output: Contribution to journalArticle

Kurashige, T, Noguchi, Y, Saika, T, Ono, T, Nagata, Y, Jungbluth, A, Ritter, G, Chen, YT, Stockert, E, Tsushima, T, Kumon, H, Old, LJ & Nakayama, E 2001, 'NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade', Cancer Research, vol. 61, no. 12, pp. 4671-4674.
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Research. 2001 Jun 15;61(12):4671-4674.
Kurashige, T. ; Noguchi, Y. ; Saika, T. ; Ono, Toshiro ; Nagata, Y. ; Jungbluth, A. ; Ritter, G. ; Chen, Y. T. ; Stockert, E. ; Tsushima, T. ; Kumon, H. ; Old, L. J. ; Nakayama, E. / NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma : Correlation with tumor grade. In: Cancer Research. 2001 ; Vol. 61, No. 12. pp. 4671-4674.
@article{2961b65cecfb4e76994fe93ab64a3979,
title = "NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade",
abstract = "NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32{\%}) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0{\%}) grade 1 (G1), 6 of 26 (23{\%}) grade 2 (G2), and 14 of 32 (44{\%}) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY. ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5{\%}) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.",
author = "T. Kurashige and Y. Noguchi and T. Saika and Toshiro Ono and Y. Nagata and A. Jungbluth and G. Ritter and Chen, {Y. T.} and E. Stockert and T. Tsushima and H. Kumon and Old, {L. J.} and E. Nakayama",
year = "2001",
month = "6",
day = "15",
language = "English",
volume = "61",
pages = "4671--4674",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma

T2 - Correlation with tumor grade

AU - Kurashige, T.

AU - Noguchi, Y.

AU - Saika, T.

AU - Ono, Toshiro

AU - Nagata, Y.

AU - Jungbluth, A.

AU - Ritter, G.

AU - Chen, Y. T.

AU - Stockert, E.

AU - Tsushima, T.

AU - Kumon, H.

AU - Old, L. J.

AU - Nakayama, E.

PY - 2001/6/15

Y1 - 2001/6/15

N2 - NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY. ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.

AB - NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY. ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.

UR - http://www.scopus.com/inward/record.url?scp=0035875056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035875056&partnerID=8YFLogxK

M3 - Article

C2 - 11406534

AN - SCOPUS:0035875056

VL - 61

SP - 4671

EP - 4674

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 12

ER -